Faculty Profile

Dr. Aditi Shastri, M.B.B.S.

Aditi Shastri, M.B.B.S.

Assistant Professor, Department of Medicine (Oncology)

Professional Interests

I am a board certified hematologist and medical oncologist. I specialize in caring for patients with hematologic malignancies and specifically myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and aplastic anemia (AA).

I have a strong interest in exploring novel treatment approaches for myelodysplatic syndromes (MDS) and Acute Myeloid Leukemia (AML) after the failure of therapy with hypomethylating agents. I specifically focus on therapeutically targetting the transcription factor STAT3 in MDS and AML. I am an advocate for addressing health disparities across the spectrum of cancer care and I enagage in health disparities research with the use of large clinical datasets.

My original research and reviews have been published in leading peer reviewed journals that include Blood, Nature Reviews Cancer & the American Journal of Hematology.  My research is funded through the NIH Paul Calabresi Career Development Award (K12).  I have been an invited speaker at several conferences and forums nationally as well as internationally.

Selected Publications

Selected Publications

1. Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, BernardL, BhattacharyyaS, Lopez R, PradhanK, Giricz O, RavipatiG, WongL, ColeS, Bhagat T, Feld J, DharY, BartensteinM, ThiruthuvanathanV, WickremaA, YeH, FrankD, PellagattiA, BoultwoodJ, ZhouT, Kim Y, MacLeod R,Epling-Burnette PK, YeM, McCoonP, Woessner R, Steidl U, WillB and VermaA. Antisense STAT3 Inhibitor Decreases Viability of Myelodysplastic and Leukemic Stem Cells. Journal of Clinical Investigation, In Press

2. Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB, Verma A, Steidl U, Will B. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag. Science Translational Medicine. Sept 2018. PMID : 30209246

3. Shah UA, Chung EY, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat TD, Mai Y, Wei Y, Ishida E, Choudhary GS, Joseph A, Rice R, Gitego N, Parrish C, Bartenstein M, Goel S, Mantzaris I, Shastri A, Derman O, Binder A, Gritsman K, Kornblum N, Braunschweig I, Bhagat C, Hall J, Graber A, Ratner L, Wang Y, Ogawa S, Verma A, Ye BH, Janakiram M. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood, Aug 2018, PMID:30104217

4. Snyder R, Libby T, Raciti P, Amin B, Jacobson M, Rakheja D, Fleming K, Bartenstein M, Zhu C, Goel S, Verma AK, Shastri A. Myelodysplastic Syndrome and Sweets Syndrome Are Associated with a Mutation in Isocitrate Dehydrogenase 1. Anticancer Research. April 2018, PMID : 29599340

5. Kanna S; Choudhary G; Ramachandran N; Steidl U; Verma AK; Shastri A. STAT3 inhibition as a therapeutic strategy for leukemia. Leuk Lymphoma. 2017 Nov 22. PMID : 29164994

6. Darbinyan K*; Shastri, A*; Budhathoki, A*; Helbig, D; Pradha : :n K etall. Hispanic Ethnicity is Associated with Younger Age at Presentation and Worse Survival in Acute Myeloid Leukemia. Blood Advances.October 2017. PMID: 29296859  * Equally Contributed

7. Shastri A; Mantaris I; Yu Y; Janakiram M; Verma A; Barta SK. Sites of Extranodal Invovlement Are Prognostic in Patients with Stage 1 Follicular Lymphoma: An Analysis of the Surveillance, Epidemiology and End Results Database. Oncotarge. Jul 2017. PMID: 29108238

8. Shastri A; Budhathoki A; Barta S; Kornblum N; Derman O; Battini R; Raghupathy R; Verma A; Frenette P; Braunschweig I; Janakiram M. Stimulation of Adrenergic Activity by Desipramine Enhances Hematopoietic Stem and Progenitor Cell Mobilization along with G-CSF in Multiple Myeloma. Am J Hematol. 2017 Jul 4. PMID: 28675459

9. Shastri A; Will B; Steidl U; Verma A Stem Cell Alterations In Myelodysplastic Syndromes. Blood, 2017 Feb, PMID: 28159737

10. Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski JP, Braunschweig I, Verma A. High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort. Leukemia. 2016 Aug;30. PMID :27125205

11. Zell M, Assal A, Derman O, Kornblum N, Battini R, Wang Y, Narasimhulu DM, Mantzaris I, Shastri A, Verma A, Ye H, Braunschweig I, Janakiram M. Adult T-Cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy. Oncotarget. 2016 Jun 22. PMID:27341021

12. Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S, Bhagat TD, Bhattacharyya S, Assal A, Shastri A, Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias LC, Burgess LE, Pradhan K, Steidl U, Verma A. Pexmetinib : A Novel Dual Inhibitor of Tie2 and p38MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes & Acute Myeloid Leukemia. Cancer Res. 2016 Aug 15. PMID : 27287719

13. Assal A, Dong B, Khan H, Medavarapu R, Shastri A, Pradhan K, Friedman E, Mantzaris I, Janakiram M, Battini R, Kornblum N, Yu Y, Verma A, Braunschweig I, Derman O. Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor.Leuk Lymphoma. 2016 Feb 17:1-4. PMID:26886689

14. Schinke, C, Giricz O, Li W, Shastri A, Gordon S, Barreyro L, Bhagat T, Bhattacharya S, Will B, Steidl U, Verma A. IL-8/CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells, Blood, 2015 Mar, PMID: 25810490

15. Shastri A, Shastri SS. Cancer screening and prevention in low-resource environments.Nature Reviews Cancer, 2014 Dec; PMID: 25355377

16. Daver N,* Shastri A,* Kadia T, Quintas-Cardama A, Pemmaraju N, Jabbour E, Konopleva M, O’Brien S, Pierce S, Cortes J, Kantarjan H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leukemia Research 2014 Jul, PMID: 25047979 * Equally Contributed

17. Daver N, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res. 2013 Jul 24, PMID: 23890523

More Information About Dr. Aditi Shastri

Clinical Appointments

Research Interests

Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.

Montefiore Medical Center
111 East 210th Street
Bronx, NY 10467

Tel: 718.920.4826
Fax: 718.798.7474

Research Information